Proponents of the R&D capitalization method have long argued that expensing R&D incentivizes myopic managers to cut R&D to manage short-term profits, leading to underinvestment in R&D. However, we argue that R&D capitalization is not a panacea. Using a sample of U.S. software firms from 2007 to 2010, we document the first archival empirical evidence that R&D capitalization can lead to subsequent over-investment in R&D. This finding is consistent with the view that, to save their reputation, managers of R&D capitalizing firms are reluctant to report impairment of capitalized R&D. Consequently, capitalizing firms tend to continue those R&D projects with bleak prospects and thus over-invest in R&D. A further analysis indicates that effective monitoring from a firm's board of directors can discipline managers for overinvestment in R&D.
In order to continuously optimize website functionality and user experience, this website uses cookies analysis technology for website operation, analysis, and personalized services.
If you continue to browse this website, it means you agree to the use of cookies on this website.